Comparing the efficacy of bupropion and amantadine on sexual dysfunction induced by a selective serotonin reuptake inhibitor

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201409275280N17

Enrollment

Registered

2014-10-27

Start date

2011-05-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sexual dysfunction. Sexual dysfunction, not caused by organic disorder or disease

Interventions

Intervention 1: The patients were given bupropion 200mg/day for the period of4 weeks. Intervention 2: patients were assigned to another group and were given amantadine 200 mg/day for the period of4 w

Treatment - Drugs

The patients were given bupropion 200mg/day for the period of4 weeks.

patients were assigned to another group and were given amantadine 200 mg/day for the period of4 weeks.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria: patients who had a diagnosis of Major depression disorder; were in remission while taking a stable dose of Selective Serotonin Reuptake Inhibitors for at least 8 weeks; exclusion criteria:patients with any previous sexual dysfunction ; relapse of major depression;body mass index of = 30 kg/m; had a sexual partner with a history of sexual dysfunction.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Sexual dysfunction. Timepoint: Baseline and 4 weeks after treatment. Method of measurement: Arizona Sexual Experience Scale (ASEX).	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Farhad Faridhoseini

Mashhad University of Medical Sciences

faridhoseinif@mums.ac.ir+98 51 3711 2721

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026